Immune modulation during latent herpesvirus infection

Immunological Reviews

Volumn 245, Issue 1, 2012, Pages 189-208

  White, Douglas W ^a   Suzanne Beard, R ^b,c   Barton, Erik S ^c  

^a GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^b PURDUE UNIVERSITY   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Herpesvirus; Immune modulation; Latency; Mutualistic symbiosis; Reactivation

Indexed keywords

ACICLOVIR; CHICKENPOX VACCINE; GAMMA INTERFERON; GRANZYME B; HERPES VACCINE; INTERLEUKIN 6; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ALLERGY; ATHEROSCLEROSIS; ATOPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHLAMYDIA; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; GONORRHEA; HERPES VIRUS INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LATENT PERIOD; MULTIPLE SCLEROSIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYMBIOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TRICHOMONIASIS; VIRUS GENE;

ANIMALS; DISEASE MODELS, ANIMAL; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOMODULATION; VIRUS LATENCY;

EID: 83655196758     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2011.01074.x     Document Type: Review

References (163)

1. Pellett PE, Roizman B. The family herpesviridae: a brief introduction. In: Knipe DM, Howely PM eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2007:2479-2500.
2. Roizman B, Knipe DM, Whitley RJ. Herpes simplex viruses. In: Knipe DM, Howely PM eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2007:2501-2602.
3. Rickinson AB, Kieff E. Epstein-Barr Virus. In: Knipe DM, Howely PM eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2007:2655-2700.
4. Ganem D. Kapsoi's sarcoma-associated herpesvirus. In: Knipe DM, Howely PM eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2007:2847-2888.
5. Mocarski ES, Shenk T, Pass RF. Cytomegaloviruses. In: Knipe DM, Howely PM eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2007:2701-2772.
6. Virgin HW, Speck SH. Unraveling immunity to gamma-herpesviruses: a new model for understanding the role of immunity in chronic virus infection. Curr Opin Immunol 1999;11:371-379.
7. Hadinoto V, Shapiro M, Sun CC, Thorley-Lawson DA. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog 2009;5:e1000496.
8. Tronstein E, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. J Am Med Assoc 2011;305:1441-1449.
9. Ling PD, et al. The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis 2003;187:1571-1580.
10. Means RE, Lang SM, Jung JU. Human gammaherpesvirus immune evasion strategies. In: Arvin A, et al. eds. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press, 2007:559-586.
11. Gewurz BE, Vyas JM, Ploegh HL. Herpesvirus evasion of T-cell immunity. In: Arvin A, et al. eds. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press, 2007:1117-1136.
12. Vandevenne P, Sadzot-Delvaux C, Piette J. Innate immune response and viral interference strategies developed by human herpesviruses. Biochem Pharmacol 2010;80:1955-1972.
13. Decman V, Freeman ML, Kinchington PR, Hendricks RL. Immune control of HSV-1 latency. Viral Immunol 2005;18:466-473.
14. Callan MF. The immune response to Epstein-Barr virus. Microbes Infect 2004;6:937-945.
15. Moss P, Khan N. CD8(+) T-cell immunity to cytomegalovirus. Hum Immunol 2004;65:456-464.
16. + T cells dominate the memory compartments of exposed subjects. J Exp Med 2005;202:673-685.
17. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 2002;195:893-905.
18. + T cells specific for EBV in healthy virus carriers. J Immunol 1999;162:1827-1835.
19. + T cells and the virus-host balance. J Clin Invest 2005;115:2546-2555.
20. Sheridan BS, Knickelbein JE, Hendricks RL. CD8 T cells and latent herpes simplex virus type 1: keeping the peace in sensory ganglia. Expert Opin Biol Ther 2007;7:1323-1331.
21. van de Berg PJ, et al. Cytomegalovirus infection reduces telomere length of the circulating T cell pool. J Immunol 2010;184:3417-3423.
22. + T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. J Immunol 2001;167:2019-2029.
23. + T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers. Blood 2007;109:1138-1146.
24. + T-cell proliferation in the acute and persistent phases of a gammaherpesvirus infection. J Virol 2001;75:4435-4438.
25. Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 2010;22:223-230.
26. + CD45RA+ CD27 T cells: the potential involvement of interleukin-7 in this process. Immunology 2011;132:326-339.
27. Welsh RM, Selin LK. No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol 2002;2:417-426.
28. Welsh RM, Che JW, Brehm MA, Selin LK. Heterologous immunity between viruses. Immunol Rev 2010;235:244-266.
29. Sandalova E, et al. Contribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans. PLoS Pathog 2010;6:e1001051.
30. + T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol 2004;173:2410-2418.
31. + T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2004;2:E20.
32. + memory T cells. J Immunol 2007;179:1988-1995.
33. + T cell responses to smallpox and yellow fever vaccines. Immunity 2008;28:710-722.
34. Cornberg M, et al. CD8 T cell cross-reactivity networks mediate heterologous immunity in human EBV and murine vaccinia virus infections. J Immunol 2010;184:2825-2838.
35. + T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. J Clin Invest 2005;115:3602-3612.
36. Virgin HW, et al. Complete sequence and genomic analysis of murine gammaherpesvirus 68. J Virol 1997;71:5894-5904.
37. Barton E, Mandal P, Speck SH. Pathogenesis and host control of gammaherpesviruses: lessons from the mouse. Annu Rev Immunol 2011;29:351-397.
38. Munks MW, Cho KS, Pinto AK, Sierro S, Klenerman P, Hill AB. Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. J Immunol 2006;177:450-458.
39. + T cell inhibition of HSV-1 reactivation from neuronal latency. Science 2008;322:268-271.
40. Snyder CM, Cho KS, Bonnett EL, van Dommelen S, Shellam GR, Hill AB. Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells. Immunity 2008;29:650-659.
41. Chou JW, Zhou T, Kaufmann WK, Paules RS, Bushel PR. Extracting gene expression patterns and identifying co-expressed genes from microarray data reveals biologically responsive processes. BMC Bioinform 2007;8:427.
42. Chou JW, Paules RS, Bushel PR. Systematic variation normalization in microarray data to get gene expression comparison unbiased. J Bioinform Comput Biol 2005;3:225-241.
43. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
44. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucl Acids Res 2009;37:1-13.
45. Moorman NJ, Willer DO, Speck SH. The gammaherpesvirus 68 latency-associated nuclear antigen homolog is critical for the establishment of splenic latency. J Virol 2003;77:10295-10303.
46. Mackaness GB. The immunological basis of acquired cellular resistance. J Exp Med 1964;120:105-120.
47. Selin LK, Varga SM, Wong IC, Welsh RM. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J Exp Med 1998;188:1705-1715.
48. Barton ES, et al. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 2007;447:326-329.
49. Yager EJ, et al. gamma-Herpesvirus-induced protection against bacterial infection is transient. Viral Immunol 2009;22:67-72.
50. White DW, et al. Latent herpesvirus infection arms NK cells. Blood 2010;115:4377-4383.
51. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 2004;104:2840-2848.
52. Nguyen Y, McGuffie BA, Anderson VE, Weinberg JB. Gammaherpesvirus modulation of mouse adenovirus type 1 pathogenesis. Virology 2008;380:182-190.
53. Haque A, Rachinel N, Quddus MR, Haque S, Kasper LH, Usherwood E. Co-infection of malaria and gamma-herpesvirus: exacerbated lung inflammation or cross-protection depends on the stage of viral infection. Clin Exp Immunol 2004;138:396-404.
54. Biancotto A, et al. Evolution of SIV toward RANTES resistance in macaques rapidly progressing to AIDS upon coinfection with HHV-6A. Retrovirology 2009;6:61.
55. Lisco A, et al. Viral interactions in human lymphoid tissue: Human herpesvirus 7 suppresses the replication of CCR5-tropic human immunodeficiency virus type 1 via CD4 modulation. J Virol 2007;81:708-717.
56. Lisco A, Vanpouille C, Margolis L. War and peace between microbes: HIV-1 interactions with coinfecting viruses. Cell Host Microbe 2009;6:403-408.
57. Van de Perre P, et al. Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect Dis 2008;8:490-497.
58. Webster A, et al. Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection. Lancet 1989;2:63-66.
59. LeGoff J, et al. Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. AIDS 2007;21:1569-1578.
60. Greenblatt RM, et al. Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS 1988;2:47-50.
61. Corey L, Wald A, Celum AL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004;35:435-445.
62. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002;185:45-52.
63. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006;20:73-83.
64. Brown JM, et al. Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS 2007;21:1515-1523.
65. Gray RH, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357:1149-1153.
66. Watson-Jones D, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008;358:1560-1571.
67. Celum C, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:2109-2119.
68. Celum C, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010;362:427-439.
69. Rebbapragada A, et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS 2007;21:589-598.
70. Mosca JD, et al. Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1. Proc Natl Acad Sci USA 1987;84:7408-7412.
71. Moriuchi M, Moriuchi H, Williams R, Straus SE. Herpes simplex virus infection induces replication of human immunodeficiency virus type 1. Virology 2000;278:534-540.
72. Khan N. The immunological burden of human cytomegalovirus infection. Arch Immunol Ther Exp (Warsz) 2007;55:299-308.
73. Pawelec G, Larbi A, Derhovanessian E. Senescence of the human immune system. J Comp Pathol 2010;142(Suppl):S39-S44.
74. Gress RE, Deeks SG. Reduced thymus activity and infection prematurely age the immune system. J Clin Invest 2009;119:2884-2887.
75. Khan N, et al. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J Immunol 2004;173:7481-7489.
76. Trzonkowski P, et al. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination--an impact of immunosenescence. Vaccine 2003;21:3826-3836.
77. Wikby A, Johansson B, Olsson J, Lofgren S, Nilsson BO, Ferguson F. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol 2002;37:445-453.
78. Miles DJ, et al. Cytomegalovirus infection induces T-cell differentiation without impairing antigen-specific responses in Gambian infants. Immunology 2008;124:388-400.
79. Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Migliorini P. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2006;54:733-741.
80. Evans AS, Rothfield NF, Niederman JC. Raised antibody titres to E.B. virus in systemic lupus erythematosus. Lancet 1971;1:167-168.
81. Kang I, et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol 2004;172:1287-1294.
82. Moon UY, et al. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther 2004;6:R295-R302.
83. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997;100:3019-3026.
84. Poole BD, Gross T, Maier S, Harley JB, James JA. Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments. J Autoimmun 2008;31:362-371.
85. Ulff-Moller CJ, Nielsen NM, Rostgaard K, Hjalgrim H, Frisch M. Epstein-Barr virus-associated infectious mononucleosis and risk of systemic lupus erythematosus. Rheumatology 2010;49:1706-1712.
86. Strom BL, Reidenberg MM, West S, Snyder ES, Freundlich B, Stolley PD. Shingles, allergies, family medical history, oral contraceptives, and other potential risk factors for systemic lupus erythematosus. Am J Epidemiol 1994;140:632-642.
87. Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. J Clin Epidemiol 2002;55:982-989.
88. Kakalacheva K, Munz C, Lunemann JD. Viral triggers of multiple sclerosis. Biochim Biophys Acta 2011;1812:132-140.
89. Ascherio A, Munger KL. Epstein-Barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol 2010;5:271-277.
90. Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B. Epstein-Barr virus in pediatric multiple sclerosis. J Am Med Assoc 2004;291:1875-1879.
91. Farrell RA, et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 2009;73:32-38.
92. Peacock JW, Elsawa SF, Petty CC, Hickey WF, Bost KL. Exacerbation of experimental autoimmune encephalomyelitis in rodents infected with murine gammaherpesvirus-68. Eur J Immunol 2003;33:1849-1858.
93. Nelson DA, Petty CC, Bost KL. Infection with murine gammaherpesvirus 68 exacerbates inflammatory bowel disease in IL-10-deficient mice. Inflamm Res 2009;58:881-889.
94. + T regulatory cell activity following infection. J Immunol 2006;177:4670-4678.
95. Munz C, Lunemann JD, Getts MT, Miller SD. Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol 2009;9:246-258.
96. Niller HH, Wolf N, Ay E, Minarovits J. Epigenetic dysregulation of Epstein-Barr virus latency and development of autoimmune disease. Adv Exp Med Biol 2011;711:82-102.
97. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695-705.
98. Lunemann JD, et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med 2008;205:1763-1773.
99. + T-cell response in patients with early multiple sclerosis. Brain 2008;131:1712-1721.
100. Rose NR, Mackay IR. Molecular mimicry: a critical look at exemplary instances in human diseases. Cell Mol Life Sci 2000;57:542-551.
101. Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol 2001;2:797-801.
102. Chervonsky AV. Influence of microbial environment on autoimmunity. Nat Immunol 2010;11:28-35.
103. Mahmoudi M, Curzen N, Gallagher PJ. Atherogenesis: the role of inflammation and infection. Histopathology 2007;50:535-546.
104. Stassen FR, Vainas T, Bruggeman CA. Infection and atherosclerosis. An alternative view on an outdated hypothesis. Pharmacol Rep 2008;60:85-92.
105. Nieto FJ, et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 1996;94:922-927.
106. Sorlie PD, et al. Cytomegalovirus/herpesvirus and carotid atherosclerosis: the ARIC Study. J Med Virol 1994;42:33-37.
107. Hendrix MG, Dormans PH, Kitslaar P, Bosman F, Bruggeman CA. The presence of cytomegalovirus nucleic acids in arterial walls of atherosclerotic and nonatherosclerotic patients. Am J Pathol 1989;134:1151-1157.
108. Vliegen I, Duijvestijn A, Grauls G, Herngreen S, Bruggeman C, Stassen F. Cytomegalovirus infection aggravates atherogenesis in apoE knockout mice by both local and systemic immune activation. Microbes Infect 2004;6:17-24.
109. Krebs P, Scandella E, Bolinger E, Engeler D, Miller S, Ludewig B. Chronic immune reactivity against persisting microbial antigen in the vasculature exacerbates atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol 2007;27:2206-2213.
110. Melnychuk RM, et al. Mouse cytomegalovirus M33 is necessary and sufficient in virus-induced vascular smooth muscle cell migration. J Virol 2005;79:10788-10795.
111. Vliegen I, Duijvestijn A, Stassen F, Bruggeman C. Murine cytomegalovirus infection directs macrophage differentiation into a pro-inflammatory immune phenotype: implications for atherogenesis. Microbes Infect 2004;6:1056-1062.
112. Alber DG, Vallance P, Powell KL. Enhanced atherogenesis is not an obligatory response to systemic herpesvirus infection in the apoE-deficient mouse: comparison of murine gamma-herpesvirus-68 and herpes simplex virus-1. Arterioscler Thromb Vasc Biol 2002;22:793-798.
113. Alber DG, Powell KL, Vallance P, Goodwin DA, Grahame-Clarke C. Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse. Circulation 2000;102:779-785.
114. Weck KE, et al. Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. Nat Med 1997;3:1346-1353.
115. Martellotta F, Berretta M, Vaccher E, Schioppa O, Zanet E, Tirelli U. AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies. Curr HIV Res 2009;7:634-638.
116. Young LS, Rickinson AB. Epstein-Barr virus: 40years on. Nat Rev Cancer 2004;4:757-768.
117. Hold GL, El-Omar EM. Genetic aspects of inflammation and cancer. Biochem J 2008;410:225-235.
118. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-271.
119. Lamagna C, Aurrand-Lions M, Imhof BA. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 2006;80:705-713.
120. Manrique SZ, et al. Foxp3-positive macrophages display immunosuppressive properties and promote tumor growth. J Exp Med 2011;208:1485-1499.
121. Hippocrate A, Oussaief L, Joab I. Possible role of EBV in breast cancer and other unusually EBV-associated cancers. Cancer Lett 2011;305:144-149.
122. Mazouni C, et al. Epstein-Barr virus as a marker of biological aggressiveness in breast cancer. Br J Cancer 2011;104:332-337.
123. Michaelis M, Baumgarten P, Mittelbronn M, Driever PH, Doerr HW, Cinatl J Jr. Oncomodulation by human cytomegalovirus: novel clinical findings open new roads. Med Microbiol Immunol 2011;200:1-5.
124. Soroceanu L, Cobbs CS. Is HCMV a tumor promoter? Virus Res 2011;157:193-203.
125. Khan G, Philip PS, Al Ashari M, Houcinat Y, Daoud S. Localization of Epstein-Barr virus to infiltrating lymphocytes in breast carcinomas and not malignant cells. Exp Mol Pathol 2011;91:466-470.
126. Joshi D, Quadri M, Gangane N, Joshi R. Association of Epstein Barr virus infection (EBV) with breast cancer in rural Indian women. PLoS ONE 2009;4:e8180.
127. Nilsson C, et al. Does early EBV infection protect against IgE sensitization? J Allergy Clin Immunol 2005;116:438-444.
128. Calvani M, Alessandri C, Paolone G, Rosengard L, Di Caro A, De Franco D. Correlation between Epstein Barr virus antibodies, serum IgE and atopic disease. Pediatr Allergy Immunol 1997;8:91-96.
129. Saghafian-Hedengren S, Sverremark-Ekstrom E, Linde A, Lilja G, Nilsson C. Early-life EBV infection protects against persistent IgE sensitization. J Allergy Clin Immunol 2010;125:433-438.
130. Sidorchuk A, Lagarde F, Pershagen G, Wickman M, Linde A. Epstein-Barr virus infection is not associated with development of allergy in children. Pediatr Infect Dis J 2003;22:642-647.
131. Sidorchuk A, Wickman M, Pershagen G, Lagarde F, Linde A. Cytomegalovirus infection and development of allergic diseases in early childhood: interaction with EBV infection? J Allergy Clin Immunol 2004;114:1434-1440.
132. Saghafian-Hedengren S, et al. Herpesvirus seropositivity in childhood associates with decreased monocyte-induced NK cell IFN-gamma production. J Immunol 2009;182:2511-2517.
133. Laske N, et al. Infantile natural immunization to herpes group viruses is unrelated to the development of asthma and atopic phenotypes in childhood. J Allergy Clin Immunol 2002;110:811-813.
134. Strannegard IL, Strannegard O. Epstein-Barr virus antibodies in children with atopic disease. Int Arch Allergy Appl Immunol 1981;64:314-319.
135. Akinbami LJ, Schoendorf KC. Trends in childhood asthma: prevalence, health care utilization, and mortality. Pediatrics 2002;110:315-322.
136. Takeuchi K, et al. Prevalence of Epstein-Barr virus in Japan: trends and future prediction. Pathol Int 2006;56:112-116.
137. Figueira-Silva CM, Pereira FE. Prevalence of Epstein-Barr virus antibodies in healthy children and adolescents in Vitoria, State of Espirito Santo, Brazil. Rev Soc Bras Med Trop 2004;37:409-412.
138. Staras SA, Flanders WD, Dollard SC, Pass RF, McGowan JE Jr, Cannon MJ. Cytomegalovirus seroprevalence and childhood sources of infection: A population-based study among pre-adolescents in the United States. J Clin Virol 2008;43:266-271.
139. Chandler SH, Alexander ER, Holmes KK. Epidemiology of cytomegaloviral infection in a heterogeneous population of pregnant women. J Infect Dis 1985;152:249-256.
140. Wu P, et al. Evidence of a causal role of winter virus infection during infancy in early childhood asthma. Am J Respir Crit Care Med 2008;178:1123-1129.
141. Haine ER. Symbiont-mediated protection. Proc Biol Sci 2008;275:353-361.
142. Gonzalez JP, et al. Pathocenosis: a holistic approach to disease ecology. EcoHealth 2010;7:237-241.
143. Ending the War Metaphor: The Changing Agenda for Unraveling the Host-Microbe Relationship. Workshop Summary2006: Washington, DC.
144. Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell 2009;138:30-50.
145. Roossinck MJ. The good viruses: viral mutualistic symbioses. Nat Rev Microbiol 2011;9:99-108.
146. McGeoch DJ, Cook S, Dolan A, Jamieson FE, Telford EA. Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses. J Mol Biol 1995;247:443-458.
147. Barton ES, White DW, Virgin HW. Herpesvirus latency and symbiotic protection from bacterial infection. Viral Immunol 2009;22:3-4. author reply 5-6.
148. Felsenstein J, et al. PopG v3.3. A one-locus, two-allele genetic simulation program: University of Washington, 2008. Available from.
149. Sung H, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines 2010;9:1303-1314.
150. Schiller JT, Lowy DR. Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol 2010;64:23-41.
151. Dasgupta G, Chentoufi AA, Nesburn AB, Wechsler SL, BenMohamed L. New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev Vaccines 2009;8:1023-1035.
152. Sokal EM, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 2007;196:1749-1753.
153. Li H, Ikuta K, Sixbey JW, Tibbetts SA. A replication-defective gammaherpesvirus efficiently establishes long-term latency in macrophages but not in B cells in vivo. J Virol 2008;82:8500-8508.
154. Marin M, Zhang JX, Seward JF. Near elimination of varicella deaths in the US after implementation of the vaccination program. Pediatrics 2011;128:214-220.
155. Chaves SS, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med 2007;356:1121-1129.
156. Goldman GS. Universal varicella vaccination: efficacy trends and effect on herpes zoster. Int J Toxicol 2005;24:205-213.
157. Civen R, et al. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J 2009;28:954-959.
158. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002;360:678-682.
159. Sengupta N, et al. Varicella vaccination in Europe: are we ready for a universal childhood programme? Eur J Pediatr 2008;167:47-55.
160. Goldman GS. Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology. Vaccine 2005;23:3349-3355.
161. Rozenbaum MH, van Hoek AJ, Vegter S, Postma MJ. Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Rev Vaccines 2008;7:753-782.
162. Hansen SG, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011;473:523-527.
163. Boysen P, Eide DM, Storset SK. Natural killer cells in free-living Mus musculus have a primed phenotype. Molec Ecology 2011; doi:.